Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress


In June 2023, Lipigon Pharmaceuticals and Leaderna Therapeutics embarked on a strategic partnership to develop and commercialize Lipigon’s drug candidate Lipisense®, aimed at treating dyslipidemias such as severe hypertriglyceridemia (SHTG). This collaboration leverages the strengths of both companies to efficiently advance the clinical progress of Lipisense®. Recently, Leaderna received approval to start a Phase I study in China.